Thomas In Hyeup Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas In Hyeup Park has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Mike Dragunow
Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand
13 shared publications - Richard Lewis Maxwell Faull
Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand
10 shared publications - Maurice A. Curtis
Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand
9 shared publications Edward W. Mee
Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
6 shared publicationsElizabeth Cooper
Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland 1023, New Zealand
5 shared publications- Justin Rustenhoven
Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand
5 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (17) , e70486
Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells
Brain tumors, specifically high‐grade gliomas such as glioblastoma (GBM), are challenging to treat due to the presence of physiological barriers such as blood–brain barrier (BBB) and tumor heterogeneity. Designing drugs that address these brain tumor‐specific drug discovery challenges will herald much‐needed breakthroughs for this patient population. This study presents a proof of concept for the in vitro cellular activity of the multitargeted kinase inhibitor crizotinib conjugated to BBB‐crossing heptamethine cyanine dyes decorated with various functional groups in four patient‐derived GBM cell lines. We also present evidence of cellular uptake, which contributes to the observed improvement in potency of the conjugates.
- 7 September 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (17) , e70486
Open AccessSubstituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells
Brain tumors, specifically high‐grade gliomas such as glioblastoma (GBM), are challenging to treat due to the presence of physiological barriers such as blood–brain barrier (BBB) and tumor heterogeneity. Designing drugs that address these brain tumor‐specific drug discovery challenges will herald much‐needed breakthroughs for this patient population. This study presents a proof of concept for the in vitro cellular activity of the multitargeted kinase inhibitor crizotinib conjugated to BBB‐crossing heptamethine cyanine dyes decorated with various functional groups in four patient‐derived GBM cell lines. We also present evidence of cellular uptake, which contributes to the observed improvement in potency of the conjugates.
- Open Access
- 11 August 2026
- Published by Elsevier in SSRN Electronic Journal
SpikeFormer-UNet: Fully Event-Driven Spiking Neural Network for Efficient and Reliable 3D Brain Tumor Segmentation
Brain tumor segmentation from multi-sequence MRI is a fundamental task in neuro-oncological image analysis. Although convolutional and Transformer-based architectures achieve strong voxel-wise performance, reliable lesion-level segmentation remains challenging. Small tumor regions and isolated lesion-level errors often contribute only a limited number of voxels yet can substantially degrade lesion-wise performance despite strong voxel-overlap scores. These challenges highlight the need for models that improve object-level consistency while suppressing spurious predictions. In this work, we investigate Transformer-based spiking neural networks (Trans-SNNs) for 3D brain tumor segmentation, motivated by their sparse event-driven computation and ability to model long-range dependencies, which may be suitable for capturing the highly sparse distribution of tumor regions. We propose SpikeFormer-UNet, a fully event-driven encoder-decoder architecture. To improve spatial representation, we introduce Spatial-Reduction Spiking Linear Self-Attention (SR-SLSA), which integrates local feature extraction with long-range dependency modeling within a unified spiking formulation. Experiments on BraTS 2020 and BraTS 2023-GLI demonstrate that SpikeFormer-UNet consistently achieves the strongest lesion-wise performance while maintaining competitive voxel-wise accuracy. It achieves mean lesion-wise Dice scores of 82.93% on BraTS 2020 and 83.67% on BraTS 2023-GLI, compared with 79.02% and 81.73% for the strongest baselines, respectively, with voxel-wise Dice scores of 86.91% and 87.04%. External validation on the UCSF-PDGM and Auckland Hospital dataset further confirms robust lesion-wise generalization across imaging sources and protocols. Ablation analysis shows that replacing spiking neurons with continuous-valued activations primarily reduces lesion-wise performance, supporting the benefit of sparse computation. These findings provide evidence that event-driven Trans-SNNs may improve lesion-level reliability in medical image segmentation.
- 11 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpikeFormer-UNet: Fully Event-Driven Spiking Neural Network for Efficient and Reliable 3D Brain Tumor Segmentation
Brain tumor segmentation from multi-sequence MRI is a fundamental task in neuro-oncological image analysis. Although convolutional and Transformer-based architectures achieve strong voxel-wise performance, reliable lesion-level segmentation remains challenging. Small tumor regions and isolated lesion-level errors often contribute only a limited number of voxels yet can substantially degrade lesion-wise performance despite strong voxel-overlap scores. These challenges highlight the need for models that improve object-level consistency while suppressing spurious predictions. In this work, we investigate Transformer-based spiking neural networks (Trans-SNNs) for 3D brain tumor segmentation, motivated by their sparse event-driven computation and ability to model long-range dependencies, which may be suitable for capturing the highly sparse distribution of tumor regions. We propose SpikeFormer-UNet, a fully event-driven encoder-decoder architecture. To improve spatial representation, we introduce Spatial-Reduction Spiking Linear Self-Attention (SR-SLSA), which integrates local feature extraction with long-range dependency modeling within a unified spiking formulation. Experiments on BraTS 2020 and BraTS 2023-GLI demonstrate that SpikeFormer-UNet consistently achieves the strongest lesion-wise performance while maintaining competitive voxel-wise accuracy. It achieves mean lesion-wise Dice scores of 82.93% on BraTS 2020 and 83.67% on BraTS 2023-GLI, compared with 79.02% and 81.73% for the strongest baselines, respectively, with voxel-wise Dice scores of 86.91% and 87.04%. External validation on the UCSF-PDGM and Auckland Hospital dataset further confirms robust lesion-wise generalization across imaging sources and protocols. Ablation analysis shows that replacing spiking neurons with continuous-valued activations primarily reduces lesion-wise performance, supporting the benefit of sparse computation. These findings provide evidence that event-driven Trans-SNNs may improve lesion-level reliability in medical image segmentation.
- Open Access
- 22 April 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2) , 201216
AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation
- 22 April 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2) , 201216
Open AccessAAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1)
Global insights into brain tumor registries: Lessons for countries establishing a national brain tumor registry
Brain tumor registries around the world have significantly contributed to the clinical, scientific, and epidemiological understanding of brain tumors. The success of these registries has prompted many other countries to create such resources for their own populations. This narrative review compares the construction, structure, and function of brain tumor registries in the United States, China, Japan, Canada, England, Australia, Austria, Denmark, and Sweden, drawing key learnings from each. Brain tumor registries from three large, medium, and small countries were identified, and their establishment, organizational structure, and primary functions were examined. This analysis found eight key considerations for establishing a national clinical registry: (1) clearly defining the aims and objectives of the registry, (2) assessing the role of supportive legislation, (3) evaluating various registry structures, (4) assessing existing registry infrastructure, (5) weighing the benefits and drawbacks of government involvement, (6) recognizing the role of specialist centers, (7) ensuring futureproofing, and (8) prioritizing comprehensive population coverage. These findings were then applied to the New Zealand context to demonstrate how such learnings can be considered by countries wishing to establish their own registry. This review provides a practical framework for nations seeking to develop similar clinical registries.
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1)
Open AccessGlobal insights into brain tumor registries: Lessons for countries establishing a national brain tumor registry
Brain tumor registries around the world have significantly contributed to the clinical, scientific, and epidemiological understanding of brain tumors. The success of these registries has prompted many other countries to create such resources for their own populations. This narrative review compares the construction, structure, and function of brain tumor registries in the United States, China, Japan, Canada, England, Australia, Austria, Denmark, and Sweden, drawing key learnings from each. Brain tumor registries from three large, medium, and small countries were identified, and their establishment, organizational structure, and primary functions were examined. This analysis found eight key considerations for establishing a national clinical registry: (1) clearly defining the aims and objectives of the registry, (2) assessing the role of supportive legislation, (3) evaluating various registry structures, (4) assessing existing registry infrastructure, (5) weighing the benefits and drawbacks of government involvement, (6) recognizing the role of specialist centers, (7) ensuring futureproofing, and (8) prioritizing comprehensive population coverage. These findings were then applied to the New Zealand context to demonstrate how such learnings can be considered by countries wishing to establish their own registry. This review provides a practical framework for nations seeking to develop similar clinical registries.
- Open Access
- 11 January 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-20
Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate
Glioblastoma is the most common and aggressive primary brain tumour in adults. The development of anti-brain cancer agents are challenged by the blood-brain barrier and the resistance conferred by the local tumour microenvironment. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence compounds that have recently emerged as promising agents for drug delivery. We conjugated palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, to an HMCD, MHI-148, and conducted drug activity analysis on primary patient-derived glioblastoma cell lines. In addition to the expected cytostatic activity, our in vitro studies revealed that palbociclib-MHI-148 conjugate resulted in an almost 100-fold increase in cytotoxicity compared to palbociclib alone. This shift of palbociclib from cytostatic to cytotoxic when conjugated to MHI-148 was due to increased DNA damage, as indicated by an increase in γH2AX foci, followed by an increased expression of key extrinsic apoptosis genes, including TP53, TNFR1, TRAIL, FADD and caspase 8. In addition, we observed a time-dependent increase in the cell surface expression of TNFR1, consistent with an observed increase in the secretion TNFα, followed by TNFR1 endocytosis at 48 h. The treatment of patient GBM cells with the palbociclib-MHI-148 conjugate prevented TNFα-induced NFκB translocation, suggesting conjugate-induced TNFR1 signalling favoured the TNFR1-mediated apoptotic response rather than the pro-inflammatory response pathway. Notably, pharmacological inhibition of endocytosis of TNFR1, and siRNA-knockdown of TNFR1 reversed the palbociclib-MHI-148-induced cell death. These results show a novel susceptibility of glioblastoma cells to TNFR1-dependent apoptosis, dependent on inhibition of canonical NFκB signalling using our previously reported palbociclib-HMCD conjugate.
- 11 January 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-20
Open AccessInvolvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate
Glioblastoma is the most common and aggressive primary brain tumour in adults. The development of anti-brain cancer agents are challenged by the blood-brain barrier and the resistance conferred by the local tumour microenvironment. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence compounds that have recently emerged as promising agents for drug delivery. We conjugated palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, to an HMCD, MHI-148, and conducted drug activity analysis on primary patient-derived glioblastoma cell lines. In addition to the expected cytostatic activity, our in vitro studies revealed that palbociclib-MHI-148 conjugate resulted in an almost 100-fold increase in cytotoxicity compared to palbociclib alone. This shift of palbociclib from cytostatic to cytotoxic when conjugated to MHI-148 was due to increased DNA damage, as indicated by an increase in γH2AX foci, followed by an increased expression of key extrinsic apoptosis genes, including TP53, TNFR1, TRAIL, FADD and caspase 8. In addition, we observed a time-dependent increase in the cell surface expression of TNFR1, consistent with an observed increase in the secretion TNFα, followed by TNFR1 endocytosis at 48 h. The treatment of patient GBM cells with the palbociclib-MHI-148 conjugate prevented TNFα-induced NFκB translocation, suggesting conjugate-induced TNFR1 signalling favoured the TNFR1-mediated apoptotic response rather than the pro-inflammatory response pathway. Notably, pharmacological inhibition of endocytosis of TNFR1, and siRNA-knockdown of TNFR1 reversed the palbociclib-MHI-148-induced cell death. These results show a novel susceptibility of glioblastoma cells to TNFR1-dependent apoptosis, dependent on inhibition of canonical NFκB signalling using our previously reported palbociclib-HMCD conjugate.
- Open Access
- 14 October 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac166
Single-cell image analysis reveals over-expression of organic anion transporting polypeptides (OATPs) in human glioblastoma tissue
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Whilst the role of the efflux transporters are well established in GBM, the expression and function of uptake transporters, such as the organic anion transporting polypeptide (OATP) family, are not well understood. OATPs possess broad substrate specificity that includes anti-cancer agents; therefore, we sought to investigate the expression of four OATP isoforms in human GBM cell types using patient tumor tissue. Methods: We used fluorescent immunohistochemical labeling of paraffin-embedded surgically resected tissues and single-cell image analysis methods to explore the expression of the OATP isoforms in different tumor cell types through co-labeling with cell-type specific markers, such as IBA1 (pan-myeloid), GFAP (tumor cell), PDGFRβ (stromal cell), and UEA-1-lectin (endothelial). Results: We found significant over-expression of all the OATP isoforms (OATP1A2, 2B1, 1C1 and 4A1) in GBM tumor sections when compared to non-neoplastic brain. A single-cell image analysis revealed that OATPs were significantly upregulated throughout the tumor parenchyma, with significantly higher expression found on lectin-positive blood vessels and IBA1-positive myeloid cells in GBM compared to non-tumor brain tissue. Qualitative analysis of the four OATP isoforms demonstrated greater expression of OATP4A1 in peri-necrotic regions of GBM tissue, which correlated with hypoxia-related markers within the Ivy GAP RNAseq dataset. Conclusion: Here, we demonstrate, for the first time, the protein expression of four OATPs in human GBM tissue, including upregulation within the tumor microenvironment by myeloid cells and tumor vasculature, and isoform-specific upregulation within hypoxic niches.
- 14 October 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac166
Open AccessSingle-cell image analysis reveals over-expression of organic anion transporting polypeptides (OATPs) in human glioblastoma tissue
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Whilst the role of the efflux transporters are well established in GBM, the expression and function of uptake transporters, such as the organic anion transporting polypeptide (OATP) family, are not well understood. OATPs possess broad substrate specificity that includes anti-cancer agents; therefore, we sought to investigate the expression of four OATP isoforms in human GBM cell types using patient tumor tissue. Methods: We used fluorescent immunohistochemical labeling of paraffin-embedded surgically resected tissues and single-cell image analysis methods to explore the expression of the OATP isoforms in different tumor cell types through co-labeling with cell-type specific markers, such as IBA1 (pan-myeloid), GFAP (tumor cell), PDGFRβ (stromal cell), and UEA-1-lectin (endothelial). Results: We found significant over-expression of all the OATP isoforms (OATP1A2, 2B1, 1C1 and 4A1) in GBM tumor sections when compared to non-neoplastic brain. A single-cell image analysis revealed that OATPs were significantly upregulated throughout the tumor parenchyma, with significantly higher expression found on lectin-positive blood vessels and IBA1-positive myeloid cells in GBM compared to non-tumor brain tissue. Qualitative analysis of the four OATP isoforms demonstrated greater expression of OATP4A1 in peri-necrotic regions of GBM tissue, which correlated with hypoxia-related markers within the Ivy GAP RNAseq dataset. Conclusion: Here, we demonstrate, for the first time, the protein expression of four OATPs in human GBM tissue, including upregulation within the tumor microenvironment by myeloid cells and tumor vasculature, and isoform-specific upregulation within hypoxic niches.
- Open Access
- 17 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-16
Characterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer’s disease
Platelet-derived growth factor-BB (PDGF-BB):PDGF receptor-β (PDGFRβ) signalling in brain pericytes is critical to the development, maintenance and function of a healthy blood-brain barrier (BBB). Furthermore, BBB impairment and pericyte loss in Alzheimer’s disease (AD) is well documented. We found that PDGF-BB:PDGFRβ signalling components were altered in human AD brains, with a marked reduction in vascularPDGFB. We hypothesised that reduced PDGF-BB:PDGFRβ signalling in pericytes may impact on the BBB. We therefore tested the effects of PDGF-BB on primary human brain pericytes in vitro to define pathways related to BBB function. Using pharmacological inhibitors, we dissected distinct aspects of the PDGF-BB response that are controlled by extracellular signal-regulated kinase (ERK) and Akt pathways. PDGF-BB promotes the proliferation of pericytes and protection from apoptosis through ERK signalling. In contrast, PDGF-BB:PDGFRβ signalling through Akt augments pericyte-derived inflammatory secretions. It may therefore be possible to supplement PDGF-BB signalling to stabilise the cerebrovasculature in AD.
- 17 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-16
Open AccessCharacterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer’s disease
Platelet-derived growth factor-BB (PDGF-BB):PDGF receptor-β (PDGFRβ) signalling in brain pericytes is critical to the development, maintenance and function of a healthy blood-brain barrier (BBB). Furthermore, BBB impairment and pericyte loss in Alzheimer’s disease (AD) is well documented. We found that PDGF-BB:PDGFRβ signalling components were altered in human AD brains, with a marked reduction in vascularPDGFB. We hypothesised that reduced PDGF-BB:PDGFRβ signalling in pericytes may impact on the BBB. We therefore tested the effects of PDGF-BB on primary human brain pericytes in vitro to define pathways related to BBB function. Using pharmacological inhibitors, we dissected distinct aspects of the PDGF-BB response that are controlled by extracellular signal-regulated kinase (ERK) and Akt pathways. PDGF-BB promotes the proliferation of pericytes and protection from apoptosis through ERK signalling. In contrast, PDGF-BB:PDGFRβ signalling through Akt augments pericyte-derived inflammatory secretions. It may therefore be possible to supplement PDGF-BB signalling to stabilise the cerebrovasculature in AD.
- Open Access
- 15 February 2022
- Published by Springer Nature in Journal of Medical and Biological Engineering
- Vol. 42 (1) , 38-48
Robust Quantification of Regional Patterns of Migration in Three-Dimensional Cell Culture Models
Purpose: Wound healing assays is a common two-dimensional migration model, with the spheroid assay three-dimensional migration model recently emerging as being more representative of in vivo migration behaviours. These models provide insight into the overall migration of cells in response to various factors such as biological, chemotactic and molecular agents. However, currently available analysis techniques for these assays fall short on providing quantifiable means to measure regional migration patterns, which is essential to allow a more robust assessment of drug treatments on cell migration in a chemotactic fashion. Therefore, this study aims to develop a finite element (FE) based pipeline that can objectively quantify regional migration patterns of cells. Methods: We have developed a novel FE based approach that is able to accurately measure changes in overall migration areas of 3D Glioblastoma Multiforme (GBM) spheroids that we generated using the primary cell lines from patients undergoing tumour resection surgery. We live-imaged the migration patterns of GBM spheroids and analysed them, first with the standard ImageJ method. We then performed the same analysis with the proposed FE method. Results: When compared to the standard ImageJ method, our proposed method was able to measure the changes in a more quantitative and accurate manner. Furthermore, our regional migration analysis provided means to analyse the migration pattern seen in the phantom data and our experimental results. Conclusion: Our FE based method will be a a robust tool for analysing cell migration patterns of GBM and other migrating cells in various diseases and degenerations.
- 15 February 2022
- Published by Springer Nature in Journal of Medical and Biological Engineering
- Vol. 42 (1) , 38-48
Open AccessRobust Quantification of Regional Patterns of Migration in Three-Dimensional Cell Culture Models
Purpose: Wound healing assays is a common two-dimensional migration model, with the spheroid assay three-dimensional migration model recently emerging as being more representative of in vivo migration behaviours. These models provide insight into the overall migration of cells in response to various factors such as biological, chemotactic and molecular agents. However, currently available analysis techniques for these assays fall short on providing quantifiable means to measure regional migration patterns, which is essential to allow a more robust assessment of drug treatments on cell migration in a chemotactic fashion. Therefore, this study aims to develop a finite element (FE) based pipeline that can objectively quantify regional migration patterns of cells. Methods: We have developed a novel FE based approach that is able to accurately measure changes in overall migration areas of 3D Glioblastoma Multiforme (GBM) spheroids that we generated using the primary cell lines from patients undergoing tumour resection surgery. We live-imaged the migration patterns of GBM spheroids and analysed them, first with the standard ImageJ method. We then performed the same analysis with the proposed FE method. Results: When compared to the standard ImageJ method, our proposed method was able to measure the changes in a more quantitative and accurate manner. Furthermore, our regional migration analysis provided means to analyse the migration pattern seen in the phantom data and our experimental results. Conclusion: Our FE based method will be a a robust tool for analysing cell migration patterns of GBM and other migrating cells in various diseases and degenerations.
- Open Access
Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action
The CDK4/6 inhibitor palbociclib, combined with endocrine therapy, has been shown to be effective in postmenopausal women with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. However, palbociclib is not as effective in the highly aggressive, triple-negative breast cancer that lacks sensitivity to chemotherapy or endocrine therapy. We hypothesized that conjugation of the near-infrared dye MHI-148 with palbociclib can produce a potential theranostic in triple-negative, as well as estrogen receptor-positive, breast cancer cells. In our study, the conjugate was found to have enhanced activity in all mammalian cell lines tested in vitro. However, the conjugate was cytotoxic and did not induce G1 cell cycle arrest in breast cancer cells, suggesting its mechanism of action differs from the parent compound palbociclib. The study highlights the importance of investigating the mechanism of conjugates of near-infrared dyes to therapeutic compounds, as conjugation can potentially result in a change of mechanism or target, with an enhanced cytotoxic effect in this case.
Open AccessConjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action
The CDK4/6 inhibitor palbociclib, combined with endocrine therapy, has been shown to be effective in postmenopausal women with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. However, palbociclib is not as effective in the highly aggressive, triple-negative breast cancer that lacks sensitivity to chemotherapy or endocrine therapy. We hypothesized that conjugation of the near-infrared dye MHI-148 with palbociclib can produce a potential theranostic in triple-negative, as well as estrogen receptor-positive, breast cancer cells. In our study, the conjugate was found to have enhanced activity in all mammalian cell lines tested in vitro. However, the conjugate was cytotoxic and did not induce G1 cell cycle arrest in breast cancer cells, suggesting its mechanism of action differs from the parent compound palbociclib. The study highlights the importance of investigating the mechanism of conjugates of near-infrared dyes to therapeutic compounds, as conjugation can potentially result in a change of mechanism or target, with an enhanced cytotoxic effect in this case.
- Open Access
- 1 January 2022
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology
- Vol. 10 (Suppl) , S275
Quantitative analysis of human brain tumour cell migration with machine learning and finite element modelling
Vong CK, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S275. https://doi.org/10.14791/btrt.2022.10.F-2618
- 1 January 2022
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology
- Vol. 10 (Suppl) , S275
Open AccessQuantitative analysis of human brain tumour cell migration with machine learning and finite element modelling
Vong CK, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S275. https://doi.org/10.14791/btrt.2022.10.F-2618